Publications

by | March 27, 2013 | Uncategorized

Medical Devices at EU Socialists & Democrats Workshop: an evolving debate

On 19 March 2013 a workshop on medical devices took place in the European Parliament to continue discussions over the legislative proposal presented by the European Commission in September 2012. The workshop was organised by the S&D Group (Group of the Progressive Alliance of Socialists and Democrats in the European Parliament) and was chaired by the Rapporteur for the Medical Devices report, Dagmar Roth-Behrendt MEP (Germany, S&D).

The discussion over the two proposals on Medical Devices and In Vitro Medical Devices is gearing up as the principal concerns and sticking points are becoming clearer. Representatives from the European Commission, industry, consumers organisations, academics and healthcare professionals took part in the panel discussions.

Ms Roth-Behrendt opened the event stating that the purpose of the workshop was to clarify concerns surrounding the system of approval of medical devices, as well as the assessment of clinical data and reporting of incidents. She stated that following the event, she would finalise her Rapporteur’s report, which is expected to be released at the end of March.

Key messages from the workshop :

Concerning the classification of medical devices, a clear list of high risk devices is needed to avoid future harm to patients. These types of devices needed to be checked via an assessment system. A more balanced system of classification was proposed by Monique Goyens, Director-General of the European Consumers’ Organization (BEUC).

Patient safety needs to be at the centre of the legislation regardless of the type of system in place. Ms Roth-Behrendt’s preferred system, namely centralised pre-market authorisation, is in her opinion indispensable to guarantee the safety of the patient, the transparency of the process, and even to facilitate post-market surveillance. However, Paola Testori-Coggi, Director-General of DG SANCO at the European Commission, took a different point of view. She stated that pre-market authorisation cannot avoid problems such as the PIP case; many years subsequent to placing a device on the market post-marketing surveillance is needed to prove the safety of the device as certain effects can only be known over time. Ms Testori-Coggi believes that the patient benefits from assessment based on clinical data, and affirmed that the current system is fit for this purpose. Nevertheless, she agreed on the fact that a more rigid system is needed to improve transparency, quality and patient safety.

An interesting discussion focused on the role of the Notified Bodies, their number and quality. There was a consensus that the most important issue is to provide strict rules on assuring the notified bodies’ transparency and quality, especially for those that already exist. As stressed by Dr Frank Hulstaert (MD, MSc, Senior Expert, Belgian Healthcare Knowledge Center (KCE)) more strict rules, combined with centralised assessment, should avoid unacceptable consequences such as fatalities, as different notified bodies could share data from clinical investigations. He explained that, in the current system, if three different Notified Bodies were in the process of testing the same devices and this lead to a fatality in one of them, the others were unaware, which could trigger further deaths. Another issue, especially underlined by MEP Roth-Behrendt, was the need for in-house expertise concerning the notified bodies. She would like to be sure that Notified Bodies have competent expertise to access clinical evidence from manufacturers. Most of what she said is in line with the EPHA Position on Medical Devices, which supports ”stricter supervision of notified bodies by member states, as well as more control of notified bodies over manufacturers”.

Access to data on clinical trials and reporting incidents should be considered more seriously to improve transparency and awareness. As mentioned by Professor Alan Fraser (Co-Chair of the ESC Task Force on MDs, Professor of Cardiology, Wales Heart Research Institute, Cardiff University), more clinical evidence is needed to guarantee an informed choice by physicians. “Doctors should have access to full data information from the notified bodies to make proper choices between different devices” said Professor Fraser. Manufacturers have also an important role in this field in so far as communicating their experiences of these devices. Regarding post-market surveillance, Professor Fraser stressed the need for manufacturers’ support, although conducted independently, and involving more closely the advice of professionals, academic experts and advisers. Ms Roth-Behrendt stressed the importance of revising certain provisions related to vigilance mentioned in chapter VII, e.g. articles 62 and 68, to ensure an effective reporting of incidents.

Concerns were also raised over the fee system described in article 40. The Rapporteur would like to see a clearer, more transparent system to avoid any type of competition between notified bodies working on different classes of devices. For Gert Bos (President of The European Association for MDs of NBs (Team-NB)) a centralised fee system can increase the price compared to the current average, and it would run the risk that some manufacturers have to close business. Different prices are also unfair for patients as manufacturers would inevitably choose the least expensive notified body.

Ms Roth-Behrendt also proposed extending the mandate of the European Medicines Agency (EMA) to oversee the safety and control of medical devices as, as it is a centralised agency it should be able to provide the required competence and oversight.

Next steps:

  • End of March: Release of the European Parliament draft report on the proposal on Medical Devices.

EPHA related articles:

Get the EPHA Newsletter

The best of our activities, right in your inbox!